US OptionsDetailed Quotes
SLS250117P2500
- 1.40
- 0.000.00%
15min DelayTrading Jan 17 16:00 ET
0.00High0.00Low
0.00Open1.40Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-10.22%PremiumJan 17, 2025Expiry Date1.50Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.71Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sellas Life Sciences Stock Discussion
Sign in to post a comment
$Sellas Life Sciences (SLS.US)$ Reuters· just
Sellas Life Sciences Group Inc: 80% Of Randomly Selected Regal Gps Patients Showed a Specific T-Cell Immune Response! Trial to continue without modification
Sellas Life Sciences Group Inc: 80% Of Randomly Selected Regal Gps Patients Showed a Specific T-Cell Immune Response! Trial to continue without modification
14
$Sellas Life Sciences (SLS.US)$
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Thursday, 23rd January at 8:10 am
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification –
- Based on a Review of Unblinded Data, the IDMC Confirmed that GPS Ex...
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Thursday, 23rd January at 8:10 am
- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification –
- Based on a Review of Unblinded Data, the IDMC Confirmed that GPS Ex...
$Sellas Life Sciences (SLS.US)$ SELLAS Life Sciences Group (NASDAQ: SLS) outlined key business objectives for 2025, highlighting two major upcoming milestones. The company expects an interim analysis of its Phase 3 REGAL study by an Independent Data Monitoring Committee in January 2025, which will determine whether to stop the trial early for efficacy, stop for futility, or continue without modification.
Additionally, full topline Phase 2 data for SLS009 (tambiciclib) in Acute Myeloid Leu...
Additionally, full topline Phase 2 data for SLS009 (tambiciclib) in Acute Myeloid Leu...
$Sellas Life Sciences (SLS.US)$
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Tuesday, 10th December at 8:30 am
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
- REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
- Company to Host Webcast Call Today at 9:00 am ET
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Tuesday, 10th December at 8:30 am
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis –
- REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 -
- Company to Host Webcast Call Today at 9:00 am ET
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: ...
$Sellas Life Sciences (SLS.US)$ SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Relat...
$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Monday, 9th December at 8:45 am
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Monday, 9th December at 8:45 am
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AM...
1
$Sellas Life Sciences (SLS.US)$
“SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”
“SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses”
1
$Sellas Life Sciences (SLS.US)$ Reuters· 2 mins ago
Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies
Sellas: Asxl1 Mutations Predictably Identified in Colorectal Cancer and Non-Small Cell Lung Cancer in Addition to Hematologic Malignancies
$Sellas Life Sciences (SLS.US)$
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
1 minute ago, 5:45 AM PST
Via GlobeNewswire
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –
- ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell Lung Cancer (NSCLC) in Add...
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
1 minute ago, 5:45 AM PST
Via GlobeNewswire
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –
- ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell Lung Cancer (NSCLC) in Add...
No comment yet
TranceHead OP :